Member Info for Ssccss

Obviously, the dilution makes getting back to above 6 harder than it was before. Plus I actually don't know what happens if SP becomes so low that Mint can't get the rest of their 12m back. Also, I don't know how easy it is to cancel the CLN, in terms of where will Hemo get other money and what are the terms and penalties. So many unknowns for me but I'm still researching.

For me, I had assumed that the Mint deal was to help Hemo pay for their part of the collaboration with Global co- and to use on some other products. I unfortunately did think global co would take the option as they had been working together for years and the product is apparently doing very well. I also mistakenly thought Global co would provide significant funding for CDX, so Hemo would not be so reliant on Mint money.
Therefore, I didn't foresee a substantial drop in SP so the Mint deal didn't look so bad.

However, I then realised how vague the RNS was with regards to who the option was being taken by. But I hesitated to act and it was too late... massive drop on news of Hemo being the ones taking the option. This means more risk for Hemo and more funds needed. In this scenario, with a much lower SP and no current future prospects of incoming funds, the Mint deal is much higher risk. Add to that, the fact Mint have converted so often recently and that the relationship with Hemo appears to have broken down... and here we are. Reading that back is rather embarrassing how many incorrect assumptions I made. Happy for others to fill in anything I have missed and would like to hear others perspectives.

Will take a look later Pumpky.

Looks interesting but is another small company so isn't going to help the immediate financial situation.

It says 18th april 2021...

I don't understand? What is that? Why not in an RNS? I haven't heard of this collaboration before. Is it old news? I can't see a date on the article. How strange.

I have to agree, he didn't reassure me at all regarding the CLN. Didn't sound like he had any idea how it is going to play out and he's looking to get out of it now that the relationship with Mint has broken down. Surely, Hemo must have know this could happen. Maybe they did it as a bluff thinking Global co would take the option. However, global co not taking the option has triggered a negative cycle otherwise known as death spiral finance. Hemo must have been desperate to take the CLN. Only substantial news will save things now.

People are allowed to change their perspectives based upon new information...it's called learning.

Amur, do you mean CDX or the CBR platform regarding covid?

Received even

I would think if they had recieved approval, they would RNS it.

I think there will be quite a few of us trying to make that decision. You are not alone MrIndia!

No idea. That's why I haven't averaged down yet. Many others have though.

Unless of course, there is a major positive development in the next few months...wait and see I guess.

The-Hat, you are assuming a steady flow of good news to sustain the SP in the face of conversions and dilution, before the clinical trials can reasonably support that CDX works. I'm not saying it is impossible to pull off. I'm just saying it's very difficult and possibly unlikely.

Very strange price action.

Yes Chris, I myself have been here 2 years. I understand patience is needed in terms of product development, clinical trials and realising value. However, I'm concerned Hemo might not get there as badly structured CLN's can backfire and put a company out of business in some scenarios.

Since 1st april, there has been a good consistent progress. Very timely in comparison to previously. Sounding positive.

Maybe JHFH, my understanding at the moment was that they are forward selling but I will do more research.

The price used for the conversion (the "Conversion Price") will be equal to a 10 per cent. discount to the lesser of (i) 125 per cent. of the closing-bid price as reported by Bloomberg for one Ordinary Share one trading day before the relevant Issue Date (subject to adjustment to reflect any sub-division or consolidation of the Ordinary Shares) and (ii) the lowest closing bid-price as reported by Bloomberg for an Ordinary Share from the three consecutive trading days ending on the day prior to the date of service of the relevant conversion notice (or if such conversion notice is served after 4.35pm on any such date, then the three consecutive trading days ending on the day such conversion notice is served. In no event shall the Conversion Price be less than the nominal value of an Ordinary Share.